Abstract
Longitudinal studies are needed to evaluate the SARS-CoV-2 mRNA vaccine antibody response under “real-world” conditions. This longitudinal study investigated the quantity and quality of SARS-CoV-2 antibody response in 846 specimens from 350 subjects: comparing BNT162b2-vaccinated individuals (19 previously diagnosed with COVID-19 [RecoVax]; 49 never been diagnosed [NaïveVax]) to 122 hospitalized unvaccinated (HospNoVax) and 160 outpatient unvaccinated (OutPtNoVax) COVID-19 patients.
NaïveVax experienced a delay in generating SARS-CoV-2 total antibody levels (TAb) and neutralizing antibodies (SNAb) after the 1st vaccine dose (D1), but a rapid increase in antibody levels was observed after the 2nd dose (D2). However, these never reached the robust levels observed in RecoVax. In fact, NaïveVax TAb and SNAb levels decreased 4-weeks post-D2 (p=0.003;p<0.001). For the most part, RecoVax TAb persisted throughout this study, after reaching maximal levels 2-weeks post-D2; but SNAb decreased significantly ∼6-months post-D1 (p=0.002). Although NaïveVax avidity lagged behind that of RecoVax for most of the follow-up periods, NaïveVax did reach similar avidity by ∼6-months post-D1. These data suggest that one vaccine dose elicits maximal antibody response in RecoVax and may be sufficient. Also, despite decreasing levels in TAb and SNAb overtime, long-term avidity maybe a measure worth evaluating and possibly correlating to vaccine efficacy.
Competing Interest Statement
ZZ has received seed instruments from ET Healthcare and sponsored research funding from ET Healthcare and Roche Diagnostics. SRB has received sponsored research funding from Roche Diagnostics. The remaining authors have declared that no conflict of interest exist.
Funding Statement
ZZ has received seed instruments from ET Healthcare and sponsored research funding from ET Healthcare and Roche Diagnostics. SRB has received sponsored research funding from Roche Diagnostics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The retrospective (IRB#2003021671) and prospective (IRB#2011022929; IRB#2004021831) studies in this manuscript were performed at NewYorkPresbyterian Hospital/Weill Cornell Medical Center (NYP/WCMC) with approval by the Institutional Review Board of Weill Cornell Medicine (WCM).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement: ZZ has received seed instruments from ET Healthcare and sponsored research funding from ET Healthcare and Roche Diagnostics. SRB has received sponsored research funding from Roche Diagnostics. The remaining authors have declared that no conflict of interest exists.
Abbreviation
- COVID-19
- Coronavirus Disease-2019
- D1
- 1st dose vaccine
- D2
- 2nd dose vaccine
- DAOS
- days after onset of symptoms
- dR
- relative dissociation rate
- ED
- Emergency Department
- EUA
- emergency use authorization
- FDA
- U.S. Food and Drug Administration
- HospNoVax
- hospitalized acutely infected non-vaccinated cohort
- NaïveVax
- naive vaccinated cohort
- N
- nucleocapsid
- NYP
- New York Presbyterian
- OutPtNoVax
- convalescent non-vaccinated COVID-19 outpatients
- PI
- days post-infection (SARS-CoV-2)
- PRNT
- plaque reduction neutralization test
- PsV
- pseudovirus neutralization test
- RBD
- receptor-binding domain
- RecoVax
- recovered vaccinated cohort
- RFU
- relative fluorescence unit
- RT-PCR
- real-time reverse transcription polymerase chain reaction
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SD
- standard deviation
- SNAB
- surrogate neutralizing antibody
- TAb
- total antibody
- WCMC
- Weill Cornell Medical Center.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos